Contact

All Publications

  • Human vaccine responses regulated by parallel cytokine pathways. Nature immunology Chen, G., Guo, J., Heath, J., Prestwood, T. R., Kwon, W. J., Smith, A. R., Nguyen, T. T., Kathuria, K. R., Sola, E., Sangare, A., Mallajosyula, V., Furuichi Fong, R., Mohsin, A., Chen, L., Siva, O., Padilla, C., Tan, M., Dekker, C. L., Grant, P., Lu, Y., Greenberg, H. B., Robinson, W. H., Blish, C., Shen-Orr, S. S., Salehi, A., Maecker, H. T., Khatri, P., Utz, P. J., Chien, Y. H., Davis, M. M. 2026

    Abstract

    Human vaccine responses vary widely, but the determinants remain incompletely defined. Here we analyzed 66 cytokines across four inactivated influenza vaccine (IIV) cohorts over five seasons (n = 581) and identified baseline serum interleukin (IL)-18 and interferon (IFN)-β as correlates of day 28 antibody responses. To test causality, we evaluated 19 cytokines in human tonsil and spleen organoids and found that type I IFNs, IL-21 and IL-12, but not IL-18 or IFNγ, enhanced antibody production. The addition of IFNβ to IIV recapitulated key features of the live-vaccine cytokine program. IL-12 and IL-21 defined a parallel pathway independent of type I IFNs, with IL-12 inducing IL-21 in humans, unlike in mice. Delivery of IL-21 or IFNβ via mRNA lipid nanoparticles in vivo promoted long-lived plasma cell formation. Together, these findings define parallel pathways that regulate vaccine immunity. Our approach unites high-throughput organoid testing and human cohort studies, establishing a human-centric platform to identify adjuvant candidates.

    View details for DOI 10.1038/s41590-026-02547-x

    View details for PubMedID 42286357

    View details for PubMedCentralID 7608473